Such MDA-protein-like adducts modify proteins to change their activity, with significant impacts on chemo-resistance (AKR1B10, GST), cell growth (Pin1, EGFR, PPAR), survival (GCL, proteasome, PPAR) and metastatic capacity(α-elonase) in cancers such as glioma, leukemia, breast, renal and colon cancer. This evidence concerns the gene PPARA and glioma.